NCT02288676 DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics
| NCT ID | NCT02288676 |
| Status | Recruiting |
| Phase | — |
| Sponsor | McGill University |
| Condition | Ovarian Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,200 participants |
| Start Date | 2014-01 |
| Primary Completion | 2025-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,200 participants in total. It began in 2014-01 with a primary completion date of 2025-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers from a uterine pap test. A saliva sample is also collected that acts as an internal control and has the ability to detect deleterious germline mutations associated with common hereditary cancers (such as breast, ovarian, endometrial, colon, and pancreatic cancers). A machine learning classifier is then used to discriminate between cancer and benign disease.
Eligibility Criteria
Case Inclusion: * Subjects should have suspected or confirmed cancer of the upper genital tract. * Participant will undergo surgery for tumour removal. Control inclusion: • Subjects should be scheduled to have a hysterectomy, bilateral salpingectomy, with or without bilateral oophorectomy, for presumed benign disease.
Contact & Investigator
Dr Ioannis Ragoussis, PhD
STUDY DIRECTOR
McGill Genome Center
Frequently Asked Questions
Who can join the NCT02288676 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Ovarian Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02288676 currently recruiting?
Yes, NCT02288676 is actively recruiting participants. Contact the research team at lucy.gilbert@mcgill.ca for enrollment information.
Where is the NCT02288676 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT02288676 clinical trial?
NCT02288676 is sponsored by McGill University. The principal investigator is Dr Ioannis Ragoussis, PhD at McGill Genome Center. The trial plans to enroll 1,200 participants.